Remicade infliximab: Phase III data; sBLA under review; marketed to reduce the signs and symptoms of RA and to treat Crohn's disease

Additional X-ray data from JNJ subsidiary Centocor Inc.'s 348-patient Phase III ATTRACT trial showed

Read the full 141 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE